| Literature DB >> 21126351 |
Yu-Cheng Lin1, Jong-Dar Chen, Su-Huey Lo, Pau-Chung Chen.
Abstract
BACKGROUND: Metabolic syndrome (MetS) management programs conventionally focus on the adults having MetS. However, risk assessment for MetS development is also important for many adults potentially at risk but do not yet fulfill MetS criteria at screening. Therefore, we conducted this follow-up study to explore whether initial screening records can be efficiently applied on the prediction of the MetS occurrence in healthy middle-aged employees.Entities:
Mesh:
Year: 2010 PMID: 21126351 PMCID: PMC3003648 DOI: 10.1186/1471-2458-10-747
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Baseline characteristics for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially
| Variable* | Overall N = 1384 | Without MetS outcome | With MetS outcome | |
|---|---|---|---|---|
| n = 1209 | n = 175 | |||
| Age (years) | 32.3 ± 6.5 | 32.1 ± 6.5 | 33.3 ± 6.6 | 0.04 |
| Body mass index (kg/m2) | 23.0 ± 3.0 | 22.6 ± 2.9 | 25.8 ± 2.5 | <0.01 |
| Waist (cm) | 75.6 ± 8.6 | 74.4 ± 8.2 | 83.3 ± 7.4 | <0.01 |
| Systolic blood pressure (mmHg) | 117.0 ± 14.3 | 116.0 ± 14.1 | 124.2 ± 14.2 | <0.01 |
| Diastolic blood pressure(mmHg) | 71.7 ± 9.2 | 71.0 ± 9.0 | 76.4 ± 9.0 | <0.01 |
| Fasting blood sugar (mg/dl) | 94.3 ± 13.2 | 93.7 ± 12.0 | 97.8 ± 19 6 | <0.01 |
| Triglyceride (mg/dl) | 102.5 ± 78.0 | 97.3 ± 77.3 | 137.9 ± 73.3 | <0.01 |
| HDL cholesterol (mg/dl) | 50.5 ± 11.8 | 51.2 ± 11.7 | 46.0 ± 12.0 | <0.01 |
| Alanine aminotransferase (U/l) | 27.2 ± 26.6 | 25.5 ± 25.8 | 38.5 ± 29.3 | <0.01 |
| γ-Glutamyl transferase (U/l) | 33.4 ± 24.7 | 31.0 ± 22.2 | 49.7 ± 33.3 | <0.01 |
| Uric acid (mg/dl) | 6.6 ± 1.6 | 6.5 ± 1.6 | 7.2 ± 1.5 | <0.01 |
| Insulin (μU/ml) | 8.2 ± 5.7 | 7.8 ± 5.0 | 11.1 ± 8.9 | <0.01 |
| Adults having MetS component (count ≤ 2) | 811 (58.6%) | 657 (54.3%) | 154 (88.0%) | <0.01 |
| Male gender | 996 (72.0%) | 855 (70.7%) | 141(80.6%) | <0.01 |
| Ever been a smoker (≥ 6 cigarettes/day for ≥1 year) | 361 (26.1%) | 312 (25.8%) | 49 (28.0%) | 0.55 |
| Regular alcohol consumption (≥ 1 day/week) | 100 (7.2%) | 77 (6.4%) | 23 (13.1%) | 0.01 |
| Taking exercise ≥ 3 days/week) | 444 (32.1%) | 389 (32.2%) | 55 (31.4%) | 0.84 |
| Having snacks before sleeping (≥ 3 days/week) | 644 (46.5%) | 568 (47.0%) | 76 (43.4%) | 0.38 |
| Having snacks between meals (≥ 3 days/week) | 546 (39.5%) | 473 (39.1%) | 73 (41.7%) | 0.51 |
| HBV carrier | 256 (18.5%) | 221 (18.3%) | 35 (20.0%) | 0.59 |
| HCV carrier | 16 (1.2%) | 13 (1.1%) | 3 (1.7%) | 0.53 |
| Sonographic fatty liver | 349 (27.4%) | 278 (23.0%) | 101 (57.7%) | <0.01 |
* The upper rows are means and standard deviation (mean ± SD), and the lower rows are proportions (numbers and proportions,%). Abbreviations: HDL cholesterol, high-density lipoprotein cholesterol.
** t-tests for continual variables between groups with/without MetS outcome; χ2 tests were conducted for categorical variables between groups with/without MetS outcome
Baseline prevalence rates for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially
| 2002 baseline data, divided by MetS outcome in 2007** | ||||
|---|---|---|---|---|
| Abnormality Prevalence* | Overall N = 1384 | Without MetS outcome n = 1209 | With MetS outcome, n = 175 | |
| MetS component (not segregated) | ||||
| COB | 54 (3.9%) | 28 (2.3%) | 26(14.9%) | <0.01 |
| Hyper-GL | 284 (20.5%) | 234 (19.4%) | 50(28.6%) | 0.01 |
| HBP | 245 (17.7%) | 193 (16.0%) | 52(29.7%) | <0.01 |
| Low-HDL | 338 (24.4%) | 269 (22.2%) | 69(39.4%) | <0.01 |
| Hyper-TG | 190 (13.7%) | 139 (11.5%) | 51(29.1%) | <0.01 |
| MetS component (segregated by count and combination) | ||||
| Single component | 511 (36.9%) | 451 (37.3%) | 60 (34.3%) | 0.44 |
| Hyper-GL alone | 149 (10.8%) | 132 (10.9%) | 17(9.7%) | 0.62 |
| Low-HDL alone | 168 (12.1%) | 151 (12.5%) | 17(9.7%) | 0.27 |
| HBP alone | 115 (8.3%) | 107 (8.9%) | 8(4.6%) | 0.02 |
| Hyper-TG alone | 63 (4.6%) | 51 (4.2%) | 12(6.9%) | 0.19 |
| COB alone | 16 (1.2%) | 10 (0.8%) | 6(3.4%) | 0.07 |
| Two components | 300 (21.7%) | 206 (17.0%) | 94 (53.7%) | <0.01 |
| Low-HDL-plus-Hyper-TG | 61 (4.4%) | 43 (3.6%) | 18(10.3%) | <0.01 |
| Hyper-GL-plus-Low-HDL | 51 (3.7%) | 42 (3.5%) | 9(5.1%) | 0.34 |
| Low-HDL-plus-HBP | 42 (3.0%) | 26 (2.2%) | 16(9.1%) | <0.01 |
| Hyper-TG-plus-HBP | 31 (2.2%) | 22 (1.8%) | 9(5.1%) | 0.05 |
| Hyper-GL-plus-Hyper-TG | 30 (2.2%) | 22 (1.8%) | 8(4.6%) | 0.09 |
| COB-plus-Low-HDL | 16 (1.2%) | 7 (0.6%) | 9(5.1%) | <0.01 |
| COB-plus-HBP | 10 (0.7%) | 5 (0.4%) | 5(2.9%) | 0.06 |
| COB-plus-Hyper-GL | 7 (0.5%) | 5 (0.4%) | 2(1.1%) | 0.38 |
| COB-plus-Hyper-TG | 5 (0.4%) | 1 (0.1%) | 4(2.3%) | 0.05 |
* The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed. Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
**χ2 tests were conducted for categorical variables between groups with/without MetS outcome.
Model 1, adjusted risks for metabolic syndrome (MetS), conventionally, individual MetS-components are not separated apart
| Baseline potential risk factors* | Adjusted-OR** | 95%CI | |
|---|---|---|---|
| MetS component | |||
| COB | 7.5 | 4.0 - 14.2 | <0.01 |
| Hyper-TG | 2.4 | 1.5 - 3.7 | <0.01 |
| Hyper-GL | 2.2 | 1.4 - 3.3 | <0.01 |
| Low-HDL | 2.7 | 1.8 - 4.0 | <0.01 |
| HBP | 2.5 | 1.6 - 3.9 | <0.01 |
| Hyperuricemia | 1.0 | 0.6 - 1.6 | 0.98 |
| Sonographic fatty liver | 2.3 | 1.6 - 3.5 | <0.01 |
| Elevated alanine aminotransferase | 1.3 | 0.8 - 2.1 | 0.36 |
| Elevated γ-glutamil transferase | 2.0 | 1.3 - 3.1 | <0.01 |
| Hyperinsulinemia | 1.7 | 1.1 - 2.6 | <0.01 |
* Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, High blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity
** Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, sonographic liver enzymes, fatty liver, hepatovirus infections, hyperinsulinemia and hyperuricemia.
Model 2, adjusted risks for metabolic syndrome (MetS) using MetS-component count as potential risk factors
| Baseline potential risk factors | Adjusted-OR* | 95%CI | |
|---|---|---|---|
| MetS component count | |||
| Adults having a single MetS component | 2.8 | 1.6 - 4.7 | <0.01 |
| Adults having two MetS components | 7.3 | 4.3 - 12.6 | <0.01 |
| Hyperuricemia | 1.0 | 0.6 - 1.6 | 0.99 |
| Sonographic fatty liver | 2.4 | 1.6 - 3.6 | <0.01 |
| Elevated alanine aminotransferase | 1.3 | 0.8 - 2.1 | 0.37 |
| Elevated γ-glutamyl transferase | 2.0 | 1.2 - 3.1 | <0.01 |
| Hyperinsulinemia | 1.8 | 1.2 - 2.6 | <0.01 |
* Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, liver enzymes, sonographic fatty liver, hepatovirus infections, hyperinsulinemia and hyperuricemia.
Model 3, adjusted risks for metabolic syndrome (MetS) calculated using each MetS component and their combinations as potential risk factors
| Baseline MetS components and combinations* | Adjusted-OR** | 95%CI | Overall (N = 1384) | SI† | 95%CI |
|---|---|---|---|---|---|
| Adults having single MetS component at baseline | - | - | - | - | |
| COB alone | 9.1 | 2.8 - 29.9 | <0.01 | - | |
| Hyper-TG alone | 3.4 | 1.5 - 7.7 | <0.01 | - | |
| Hyper-GL alone | 3.0 | 1.5 - 6.0 | <0.01 | - | |
| Low-HDL alone | 2.9 | 1.4 - 5.8 | <0.01 | - | |
| HBP alone | 1.4 | 0.6 - 3.4 | 0.44 | - | |
| Adults having two MetS components at baseline | |||||
| COB-plus-Hyper-TG | 59.6 | 5.8 - 611.5 | <0.01 | 7.6 | 0.8 - 74.5 |
| COB-plus-Low-HDL | 24.6 | 7.7 - 78.2 | <0.01 | 2.8 | 0.8 - 9.2 |
| COB-plus-HBP | 14.5 | 3.6 - 59.1 | <0.01 | 2.0 | 0.5 - 8.5 |
| HBP-plus-Low-HDL | 11.7 | 5.1 - 27.0 | <0.01 | ||
| HBP-plus-Hyper-GL | 7.9 | 3.5 - 18.1 | <0.01 | ||
| COB-plus-Hyper-GL | 6.7 | 1.2 - 38.7 | <0.05 | 0.8 | 0.1 - 5.2 |
| HBP-plus-Hyper-TG | 5.8 | 2.2 - 15.4 | <0.01 | 1.6 | 0.6 - 4.3 |
| Low-HDL-plus-Hyper-TG | 5.7 | 2.7 - 12.3 | <0.01 | 1.6 | 0.7 - 3.3 |
| Hyper-GL-plus-Hyper-TG | 4.1 | 1.5 - 11.1 | <0.01 | 1.6 | 0.6 - 4.4 |
| Hyper-GL-plus-Low-HDL | 3.9 | 1.6 - 9.8 | <0.01 | 1.1 | 0.4 - 2.9 |
* Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.;.
** Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, liver enzymes, sonographic fatty liver, hepatovirus infections, hyperinsulinemia and hyperuricemia.
† SI, synergistic index, SI value exceeding 1.0 indicates the presence of synergistic interaction.
‡ NA: Not analyzed in this model, analyzed and shown in Table 4, Model 2.
SI and 95%CI in bold are considered to be statistically significant.